CTLT - Catalent, Inc.
37.94 -0.03 (-0.08%)
After hours: 4:14PM EST
| Previous Close | 37.51 |
| Open | 37.37 |
| Bid | 0.00 x 3100 |
| Ask | 46.85 x 800 |
| Day's Range | 37.16 - 38.28 |
| 52 Week Range | 34.24 - 47.87 |
| Volume | 1,157,359 |
| Avg. Volume | 846,409 |
| Market Cap | 5.515B |
| Beta (3Y Monthly) | 1.59 |
| PE Ratio (TTM) | 60.22 |
| EPS (TTM) | 0.63 |
| Earnings Date | Feb 4, 2019 - Feb 8, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 44.50 |
Markit•3 days agoSee what the IHS Markit Score report has to say about Catalent Inc.
Short interest is extremely low for CTLT with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting CTLT. ETFs that hold CTLT had net inflows of $444 million over the last one-month.
- Simply Wall St.•5 days ago
What Does Catalent Inc’s (NYSE:CTLT) P/E Ratio Tell You?
This article is written for those who want to get better at using price to earnings ratios (P/E ratios). To keep it practical, we’ll show how Catalent Inc’s (NYSE:CTLT) P/E Read More...
- Thomson Reuters StreetEvents•6 days ago
Edited Transcript of CTLT earnings conference call or presentation 6-Nov-18 1:15pm GMT
Q1 2019 Catalent Inc Earnings Call
Motley Fool•6 days agoCatalent Inc (CTLT) Q1 2019 Earnings Conference Call Transcript
CTLT earnings call for the period ending September 30, 2018.
- Simply Wall St.•6 days ago
Is Catalent Inc’s (NYSE:CTLT) CEO Incentives Align With Yours?
In 2009 John Chiminski was appointed CEO of Catalent Inc (NYSE:CTLT). This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. Read More...
- Associated Press•6 days ago
Catalent: Fiscal 1Q Earnings Snapshot
The Somerset, New Jersey-based company said it had a loss of 10 cents per share. Earnings, adjusted for one-time gains and costs, came to 28 cents per share. The results missed Wall Street expectations. ...
- Business Wire•6 days ago
Catalent, Inc. Reports First Quarter Fiscal 2019 Results
SOMERSET, N.J.-- -- Q1'19 revenue of $551.8 million increased 1% as-reported, or 3% in constant currency, from the prior-year period. Closed the acquisition of Juniper Pharmaceuticals, a European early development Center of Excellence with dose form development and clinical manufacturing capabilities. FY'19 financial guidance reaffirmed. Catalent, Inc. , the leading global provider of advanced delivery ...
- Business Wire•12 days ago
Catalent, Inc. to Present at Three Upcoming Investor Conferences
Catalent, Inc. , the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that Wetteny Joseph, Senior Vice President & Chief Financial Officer, and Thomas Castellano, Vice President Finance, Investor Relations and Treasurer will present at the following conferences in the coming weeks.
- GlobeNewswire•20 days ago
Report: Exploring Fundamental Drivers Behind The Home Depot, uniQure N.V, Catalent, Apple, BioTime, and PDL BioPharma — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Oct. 23, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Markit•23 days agoSee what the IHS Markit Score report has to say about Catalent Inc.
Catalent Inc NYSE:CTLT
- Business Wire•last month
Catalent, Inc. Announces First Quarter Fiscal Year 2019 Earnings Conference Webcast
Catalent, Inc. (CTLT) (“Catalent”), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products, today announced that it will release financial results for the first quarter of fiscal year 2019 ended September 30, 2018, before the market open on Tuesday, November 6, 2018. Catalent invites all interested parties to listen to the webcast, which will be accessible through Catalent’s website at http://investor.catalent.com. A supplemental slide presentation will also be available in the “Investors” section of Catalent’s website prior to the start of the webcast.
- GuruFocus.com•last month
Catalent Inc (CTLT) Chair, President & CEO John R Chiminski Sold $5.9 million of Shares
Chair, President & CEO of Catalent Inc (NYSE:CTLT) John R Chiminski sold 130,545 shares of CTLT on 10/01/2018 at an average price of $45.32 a share.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of CTLT earnings conference call or presentation 28-Aug-18 12:15pm GMT
Q4 2018 Catalent Inc Earnings Call
- Zacks•2 months ago
New Strong Sell Stocks for September 19th
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Markit•2 months agoSee what the IHS Markit Score report has to say about Catalent Inc.
Catalent Inc NYSE:CTLT
Markit•2 months agoSee what the IHS Markit Score report has to say about Catalent Inc.
Catalent Inc NYSE:CTLT
- Zacks•2 months ago
Catalent (CTLT) Q4 Earnings Top Estimates
Catalent (CTLT) delivered earnings and revenue surprises of 9.84% and -0.11%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•2 months ago
Catalent: Fiscal 4Q Earnings Snapshot
The Somerset, New Jersey-based company said it had net income of 61 cents per share. Earnings, adjusted for one-time gains and costs, came to 67 cents per share. The results surpassed Wall Street expectations. ...
- GlobeNewswire•2 months ago
Research Report Identifies Scientific Games, Accuray, Shake Shack, MoneyGram International, G-III Apparel Group, LTD, and Catalent with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, Aug. 28, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Scientific ...
- Business Wire•2 months ago
Catalent, Inc. Reports Fourth Quarter Fiscal 2018 Results
SOMERSET, N.J.-- -- Q4'18 revenue of $685.3 million increased 11% as-reported, or 9% in constant currency from the prior-year period. Full-year revenue of $2,463.4 million increased 19% as-reported, or 16% in constant currency from the prior-year. Closed the acquisition of Juniper Pharmaceuticals, a European early development Center of Excellence with dose form development and clinical manufacturing ...
Markit•3 months agoSee what the IHS Markit Score report has to say about Catalent Inc.
Catalent Inc NYSE:CTLT
- Business Wire•3 months ago
Catalent Completes Tender Offer for All Outstanding Shares of Juniper Pharmaceuticals, Inc.
Catalent, Inc. (CTLT) (“Catalent”), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced the successful completion of the previously announced tender offer by Catalent Boston, Inc. (“Merger Sub”), a subsidiary of Catalent Pharma Solutions, Inc. (“Parent”), Catalent’s operating subsidiary, for all of the outstanding shares of common stock of Juniper Pharmaceuticals, Inc. (JNP) (“Juniper”) at a price of $11.50 per share, net to the seller in cash, without any interest, but subject to and reduced by any required withholding of taxes. The acquisition of Juniper expands and strengthens Catalent’s offerings in formulation development, bioavailability solutions and clinical-scale oral dose manufacturing, and complements its integrated global clinical and commercial supply network.
Markit•3 months agoSee what the IHS Markit Score report has to say about Catalent Inc.
Catalent Inc NYSE:CTLT
- Moody's•3 months ago
Catalent Pharma Solutions, Inc. -- Moody's upgrades Catalent's senior secured ratings to Ba2
Moody's Investors Service ("Moody's") today upgraded Catalent Pharma Solutions, Inc.'s ("Catalent") senior secured credit facility ratings to Ba2 from Ba3. The rating agency affirmed all other ratings for Catalent, including the B1 Corporate Family Rating (CFR), B1-PD Probability of Default Rating (PDR), and the B3 rating on the unsecured notes. The upgrade of the senior secured credit facility ratings reflects the repayment of approximately $450 million of secured debt with proceeds from a recent stock offering.
Markit•3 months agoSee what the IHS Markit Score report has to say about Catalent Inc.
Short interest is extremely low for CTLT with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting CTLT. The net inflows of $523 million over the last one-month into ETFs that hold CTLT are among the lowest of the last year and appear to be slowing.
